Navigation Links
Inhaled Insulin for Type 2 Diabetes Shows Mixed Results

Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
br> People who use insulin to manage their type 2 diabetes typically have to take extra insulin at mealtimes to regulate the glucose response to food. They can use short-acting injected insulin or inhaled insulin.

The review examined several clinical issues surrounding the use of inhaled insulin by patients with type 2 diabetes. It looked at how inhaled insulin compares to injected insulin as a mealtime insulin supplement for patients who are already using injected insulin daily.

The report also compared use of inhaled insulin by type 2 diabetes patients who had not previously taken insulin in any form. Inhaled insulin was compared to the effectiveness of oral antidiabetic drugs used alone and to antidiabetic drugs used with inhaled insulin.

In patients with type 2 diabetes, inhaled insulin worked as well as short-acting injected insulin to control blood glucose over three months, according to the review. However, inhaled insulin users had more trouble controlling low blood glucose hypoglycemia a common complication of diabetes medication.

Insulin is associated with hypoglycemia, said John Buse, M.D., president-elect of the American Diabetes Association. That is its most common and potentially serious complication in all of its formulations.

Among patients who had not previously taken insulin in any form, inhaled insulin alone was more effective than oral diabetes medication at controlling blood glucose levels at the three-month follow-up. When patients took oral medication plus inhaled insulin, higher rates of hypoglycemia occurred.

The Windows on Medical Technology report is published by ECRI Institute, an independent nonprofit health services research agency that researches the best approaches to improving patient care. The institute produces systematic reviews on medical devices, drugs, biotechnologies, procedures, and health services.

Jonathan Treadwell, Ph.D., senior research analyst at ECRI Institute, led a team of investigators who analyzed eight studies encompassing 1,881 patients with type 2 diabetes to make the comparisons between inhaled insulin, injected insulin, and oral medication regimens.

Despite some positive findings, the authors write, the evidence regarding inhaled insulin for patients with type 2 diabetes is still insufficient to answer many key clinical questions such as patient satisfaction, inhaled insulins effect on other complications of diabetes, on weight gain, and very importantly, the long-term effects on lung function.

One detail to note about inhaled insulin the dosing is not as precise as with injections because specific increments in doses are not as precise, Treadwell said. He added that companies who are developing inhaled insulin are working on more dose-tailored devices.

Type 2 diabetes occurs when glucose remains in the blood instead of being transported to cells as it is supposed to be. There is no cure, but the disorder can often be controlled with medication and lifestyle modifications. When these changes are insufficient to control diabetes, oral medication and sometimes insulin become necessary.

Insulin can be delivered through needle syringes, insulin pens, jet injectors and external infusion pumps. If uncontrolled, diabetes can lead to heart disease, blindness, kidney failure, nerve damage, poor circulation, amputation of limbs, and ultimately result in death.

The U.S. Food and Drug Administration first approved inhaled insulin to treat diabetes in 2006. However, inhaled insulin is contraindicated for patients who have smoked in the last six months, have lung disease, are younger than age 18 or are experiencing a bout of low-blood sugar.

Its convenience makes inhaled insulin an attractive option, although it may not be the right medication for every diabetes patient who needs insulin.

Advantage: it is inhaled; disadvantage: it is inhaled, Buse said. Its all about perspective. So if there is someone who just will not take an injection, then inhaled insulin is a big advantage.

There are six to seven classes of pills that could theoretically be tried first, Buse said. It is a fairly personal decision whether it is more convenient to use insulin in vial-and-syringe, in a pen or in an inhaler.

According to the American Diabetes Association it is unclear if delivering insulin through the lungs could result in long-term respiratory problems.

This is the reason for resistance by doctors and patients to inhaled insulin long-term lung damage, Treadwell said. Its a valid concern since it is suspected that people with diabetes already have lung problems the concern is that this form of administration would exacerbate these problems.

Its too early to say if inhaled insulin could be used to the extent that injected insulin is our review only covered six month follow-up because thats the only data currently available. The question is: Could it provide long-term glucose control without damaging effects? Treadwell said.




'"/>




Related medicine news :

1. Inhaled Steroids Safe & Effective for Children with Asthma
2. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
3. The Effectiveness Of Inhaled Corticosteroids Studied
4. The Effectiveness Of Inhaled Corticosteroids Studied
5. Inhaled nitric oxide therapy does not reduce death risk of infants
6. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
7. HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy
8. Inhaled Insulin To Be Made Available in India
9. Inhaled Insulin Could Rock The Drug Market Soon
10. High Cost Forces NHS To Reject Inhaled Insulin
11. Inhaled Cyclosporine Results In Rejection Free Survival among Lung Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: